CSIMarket
 
Benitec Biopharma Inc   (BNTC)
Other Ticker:  
 
 
Price: $5.1000 $-0.07 -1.354%
Day's High: $5.19 Week Perf: 2.82 %
Day's Low: $ 5.01 30 Day Perf: 82.12 %
Volume (M): 6 52 Wk High: $ 5.95
Volume (M$): $ 32 52 Wk Avg: $2.20
Open: $5.16 52 Wk Low: $0.16



 Market Capitalization (Millions $) 13
 Shares Outstanding (Millions) 3
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -22
 Cash Flow (TTM) (Millions $) 16
 Capital Exp. (TTM) (Millions $) 0

Benitec Biopharma Inc
Benitec Biopharma Inc is a biotechnology company headquartered in California, USA. The company specializes in the development of gene therapy treatments for various diseases using its patented gene-silencing technology called DNA-directed RNA interference (ddRNAi). This technology allows for the suppression or elimination of specific genes associated with diseases, offering a potential cure or treatment.

Benitec Biopharma has a diverse pipeline of therapeutic candidates targeting diseases such as hepatitis B, head and neck squamous cell carcinoma, and ocular diseases. The company's lead product candidate, BB-301, is being developed as a potentially curative treatment for oculopharyngeal muscular dystrophy (OPMD), a rare genetic disease.

The company's approach focuses on creating long-lasting and potentially permanent gene expression changes, providing durable treatment options for patients. In addition to its internal pipeline, Benitec Biopharma also collaborates with research institutions and pharmaceutical companies to further develop and commercialize its gene therapy platform.

Overall, Benitec Biopharma Inc is committed to advancing the field of gene therapy and providing innovative treatments for various diseases using their proprietary ddRNAi technology.


   Company Address: 3940 Trust Way Hayward 94545 CA
   Company Phone Number: 780-0819   Stock Exchange / Ticker: NASDAQ BNTC
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Benitec Biopharma Inc

Benitec Biopharma Inc: Pioneering Breakthroughs in the Biopharmaceutical Industry



Benitec Biopharma, a leading biotechnology company, recently announced the initiation of the first clinical trial for their gene therapy candidate, BB-301. This breakthrough marks a significant milestone in the field of gene therapy as it utilizes Benitec's innovative Silence and Replace DNA-directed RNA interference gene therapy platform. With the commencement of this trial, Benitec is paving the way for potential breakthroughs in the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic disorder.
The Genesis of a Revolutionary Approach:
Benitec's Silence and Replace DNA-directed RNA interference gene therapy platform is an innovative approach that utilizes gene silencing and gene replacement techniques. Unlike traditional treatments, this therapy aims to correct genetic abnormalities at their root cause rather than merely addressing symptoms. By specifically targeting the faulty genes responsible for OPMD, BB-301 offers a promising solution for patients suffering from this debilitating condition.

Clinical Study

Benitec Biopharma Advances Gene Therapy Candidate BB-301 for Oculopharyngeal Muscular Dystrophy, Setting New Milestone in Medical Research

Published Thu, Nov 30 2023 12:00 PM UTC



Benitec Biopharma, a leading biotechnology company, recently announced the initiation of the first clinical trial for their gene therapy candidate, BB-301. This breakthrough marks a significant milestone in the field of gene therapy as it utilizes Benitec's innovative Silence and Replace DNA-directed RNA interference gene therapy platform. With the commencement of ...

Benitec Biopharma Inc

BNTC Shines with Stellar First Quarter Performance in 2024, Setting the Stage for Success

In the world of finance, the performance of a company's shares is closely monitored and analyzed. This is especially true in the pharmaceutical industry, where companies often face intense scrutiny due to the potential for high profits and groundbreaking developments in the field of medicine. One such company that has recently experienced a decline in its shares is Benitec Biopharma Inc.
Over the course of the last five trading days, Benitec Biopharma Inc shares have seen a significant decrease of -10%. This decline is noteworthy and has caused the year-to-date performance of the company's shares to stand at an impressive 1854.29%. Despite this recent decrease, Benitec Biopharma Inc shares are still trading on the NASDAQ at a considerable 212.6% above their 52-week average.

Benitec Biopharma Inc

Benitec Biopharma Inc Revolutionizes the Biotech Industry with Remarkable Q2 2023 Financial Performance!

Financial News Report: Benitec Biopharma Inc Reports Loss in Fiscal Year 2023
Benitec Biopharma Inc, a major pharmaceutical preparations company, recently released its financial results for the fiscal interval ending June 30, 2023. The company reported a net loss of $-4.661 million, compared to a deficit of $-5.067 million in the corresponding reporting season a year ago.
In terms of earnings per share (EPS), Benitec Biopharma Inc experienced a decline from $-0.16 per share in the previous reporting season to $-0.17 per share in the current period. However, this is an improvement compared to the earnings of $-0.62 per share a year before the reporting season.

Benitec Biopharma Inc

Benitec Biopharma Inc. Defies Market Uncertainty with Record-Breaking Financial Performance in Q1 2023

In the midst of all the uncertainty and instability in the financial market today, there are still companies that are emerging as bullish players - one of which is Benitec Biopharma Inc.
The company has shown impressive results for the financial period ending March 31, 2023. Benitec Biopharma Inc decreased its loss per share from $-0.40 to $-0.16 when compared to the same period a year prior, and EPS improved from $-0.20 per share from the preceding reporting period. The revenue also rose by 12.5% to $0.05 million from $0.05 million in the corresponding reporting period a year ago. Furthermore, sequentially, the revenue doubled by 285.714% from $0.01 million.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com